2

Limited Life Expectancy, Human Capital and Health Investments

Year:
2013
Language:
english
File:
PDF, 661 KB
english, 2013
8

Experimental Therapeutics of Neurodegenerative Disorders: Unmet Needs

Year:
1998
Language:
english
File:
PDF, 266 KB
english, 1998
16

Huntington’s Disease

Year:
1984
File:
PDF, 1.82 MB
1984
18

Huntington disease: Clinical care and evaluation

Year:
1979
Language:
english
File:
PDF, 273 KB
english, 1979
23

Selegiline and Parkinson’s Disease

Year:
1990
Language:
english
File:
PDF, 718 KB
english, 1990
26

Juvenile-Onset Huntington Disease

Year:
2007
Language:
english
File:
PDF, 52 KB
english, 2007
31

Huntington disease: Functional Capacities in patients treated with neuroleptic and antidepressant drugs

Year:
1981
Language:
english
File:
PDF, 377 KB
english, 1981
32

Milestones in Huntington disease

Year:
2011
Language:
english
File:
PDF, 109 KB
english, 2011
36

Response to Protocol Review Scenario: Re-review not required

Year:
2010
Language:
english
File:
PDF, 55 KB
english, 2010
43

Caffeine and the antiparkinsonian response to levodopa or piribedil

Year:
1975
Language:
english
File:
PDF, 556 KB
english, 1975
44

In Memoriam: Robert J. Joynt, MD, PhD (1925-2012)

Year:
2012
Language:
english
File:
PDF, 86 KB
english, 2012
45

O.085 Huntington disease (HD): clinical features and experimental therapeutics

Year:
2009
Language:
english
File:
PDF, 57 KB
english, 2009
46

Longitudinal follow-up of SWEDD subjects in the PRECEPT Study

Year:
2014
Language:
english
File:
PDF, 336 KB
english, 2014
47

Safety of rasagiline in elderly patients with Parkinson disease

Year:
2006
Language:
english
File:
PDF, 161 KB
english, 2006
48

Neurotherapeutics, Evidence-Based Neurology, and Clinical Equipoise

Year:
1999
Language:
english
File:
PDF, 73 KB
english, 1999
49

Reporting of Randomized Clinical Trials and Other Population-Based Research

Year:
2004
Language:
english
File:
PDF, 50 KB
english, 2004
50

In memoriam

Year:
1999
Language:
english
File:
PDF, 49 KB
english, 1999